Research
Hormonal
GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.
Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.
StrongSupportsmedium confidence
The recent approvals for glucagon-like peptide-1 (GLP-1) receptor agonist (RA) semaglutide 2.4 mg and the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide as treatments for obesity have raised the bar for WL efficacy.
Why this rating
The claim is based on recent approvals and their implications.
Source
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Kaivalya Abburi et al. · Panminerva Medica · 2025
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →